Mitoxantrone as a prospective photosensitizer for photodynamic therapy of breast cancer

Photodiagnosis and Photodynamic Therapy

Volumn 9, Issue 1, 2012, Pages 46-51

  Montazerabadi, Ali Reza ^a   Sazgarnia, Ameneh ^b   Bahreyni Toosi, Mohammad Hossein ^b   Ahmadi, Amirhossein ^c,d   Shakeri Zadeh, Ali ^a   Aledavood, Amir ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Mitoxantrone; Photodynamic therapy; Photosensitizer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; MITOXANTRONE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DEATH; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT EXPOSURE; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MITOXANTRONE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 84857502737     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2011.08.004     Document Type: Article

References (35)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J Clin 1997, 47:25-27.
2. Phillips D.M., Balducci L. Current management of breast cancer. Am Fam Physician 1996, 53:657-665.
3. Clark G., Sledge G., Osborne C.K., Mc Guire W.L. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 1987, 5:55-56.
4. Ottesen G., Andersen J.A., Blichert-Toft M., Axelsson C. Frequently and types of chest wall recurrences among node negative breast cancer patients. Acta Oncol 1988, 27:601-604.
5. Allison R., Mang T., Hewson G., Snider W., Dougherty D. Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality. Cancer 2001, 91:1-8.
6. Henderson B.W., Waldow S.M., Mang T.S., et al. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res 1985, 45:572-576.
7. Weishaupt K.R., Gomer C.J., Dougherty T.J. Identification of singlet oxygen as the cytotoxic agent in photo-inactivation of a murine tumor. Cancer Res 1976, 36:2326-2329.
8. Dougherty T.J. Hematoporphyrin derivative for detection and treatment of cancer. J Surg Oncol 1980, 15:209-210.
9. Wilson B.D., Mang T.S., Stoll H., et al. Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol 1992, 128:1597-1601.
10. Baumler W., Abels C., Karrer S., et al. Photo-oxidative killing of human co-lonic cancer cells using indocyanine green and infrared light. Br J Cancer 1999, 80:360-363.
11. Vicente M.G.H. Porphyrin-based sensitizers in the detection and treatment of cancer: recent progress. Curr Med Chem Anti-Cancer Agents 2001, 1:175-194.
12. Stilts C.E., Nelen M.I., Hilmey D.G., et al. Water-soluble, coremodified porphyrins as novel, longer-wavelength-absorbing sensitizers for photodynamic therapy. Med Chem 2000, 43:2403-2410.
13. Spikes J.D. New trends in photobiology (invited review). Chlorins as photosensitizers in biology and medicine. J Photochem Photobiol B Biol 1990, 259-274.
14. Rosenthal I. Phthalocyanines as photodynamic sensitizers. Photochem Photobiol 1990, 51:351-356.
15. Bonnett R. Porphyrin and phthalocyanine photosensitizers for photodynamic therapy. Chem Soc Rev 1995, 24:19-33.
16. Svanberg K., Andersson T., Killander D., et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical δ-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol 1994, 130:743-751.
17. Allison R., Mang T.S., Wilson B.D. Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies. Semin Cutan Med Surg 1998, 17:153-163.
18. Wilson B.D., Mang T.S., Cooper R.N., Stol H. Use of photodynamic therapy for the treatment of extensive basal cell carcinomas. Facial Plast Surg 1989, 6:185-189.
19. Plambeck J.A., Lown J.W. Electrochemical studies of antitumor antibiotics: an electrochemical method of measurement of the binding of doxorubicin and daunorubicin derivatives to DNA. J Electrochem Soc 1984, 131:2556-2563.
20. Durr F.E. Biologic and biochemical effects of mitoxantrone. Semin Oncol 1987, 11:3-19.
21. Heo D.S., Park J.G., Hata K., Day R., Herberman R.B., Whiteside T.L. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res 1990, 50:3681-3690.
22. Batlle A.M. Porphyrins, porphyrias, cancer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol B 1993, 20:5-22.
23. Kennedy J.C., Pottier R.H., Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990, 6:143-148.
24. Varma S., Wilson H., Kurwa H.A., et al. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 2001, 144:567-574.
25. Andreoni A., Colasanti A., Roberti G. Excited singlet state properties of anthracenedione photosensitizers. J Photochem Photobiol B 1992, 14:319-328.
26. Hartley J.A., Forrow S.M., Souhami R.L., Reszka K. Photosensitization of humanvleukemic cells by anthracenedione antitumor agents. Cancer Res 1990, 50:1936-1941.
27. Reszka K., Kolodziejczyk P., Tsoungas P.G., Lown J.W. Photosensitization by antitumor agents. 6. Production of superoxide radical and hydrogen peroxide during illumination of diaminoanthracenediones in the presence of NADH in aqueous solutions: an EPR study. Photochem Photobiol 1988, 47:297-304.
28. Reszka K., Lown J.W. Photosensitization of anticancer agents. 8. One-electron reduction of mitoxantrone: an EPR and spectrophotometric study. Photochem Photobiol 1989, 50:625-633.
29. Myers C.E., Mimnaugh E., Yeh G., Sinha B.K. Biochemical mechanisms of tumor cell kill by the anthracyclines. Anthracycline and anthracenedione-based anticancer agents 1988, 131-162. Elsevier, New York. J.W. Lown (Ed.).
30. Hammer-Wilson M.J., Sun C.H., Ghahramanlou M., Berns M.W. In vitro and in vivo comparison of argon-pumped and diode lasers for photodynamic therapy using second generation photosensitizers. Lasers Surg Med 1998, 23:274-280.
31. Sternberg E.D., Dolphin D. Second-generation photodynamic agents: a review. J Clin Laser Med Surg 1993, 11:233-241.
32. Kanofsky J.R., Sima P.D. Preferential cytotoxicity for multidrug-resistant K 562 cells using the combination of a photosensitizer and a cyanine dye. J Photochem Photobiol B 2000, 54:136-144.
33. Paiva M.B., Saxton R.E., Letts G., et al. Laser photochemotherapy with anthracyclines on cultured human squamous carcinoma cells. Laryngoscope 1996, 106:257-262.
34. Koceva-Chyla A., Wieclawska B., Jozwiak Z., Bryszewska M. Combined effect of low-power laser irradiation and anthraquinone anticancer drug aclarubicin on survival of immortalized cells: comparison with mitoxantrone. Cell Biol Int 2006, 30:645-652.
35. Lanks K.W., Gao J.-P., Sharma T. Photodynamic enhancement of doxorubicin cytotoxicity. Cancer Chemother Pharmacol 1994, 35:17-20.